Leuko Labs

Leuko Labs, an MIT spin-out, is a medical technology company that has developed PointCheck™, a non-invasive device for monitoring white blood cell levels. The company targets chemotherapy patients, who are often immunosuppressed and at high risk for infections and febrile neutropenia.

The core technology utilizes AI and computer vision for biomedical imaging. The portable, phone-sized device works by shining light through the skin of a patient's finger to count white blood cells as they flow past a miniature lens, eliminating the need for blood draws. This process allows for frequent, at-home monitoring, which can improve clinical outcomes and reduce hospital admissions for cancer patients.

The business model appears to be centered on the sale of this medical device. The company has secured funding, including a $5 million Series A round, to validate the technology and bring it to market. The primary market is healthcare, specifically oncology, serving patients undergoing treatments that affect their immune systems.

Keywords: non-invasive monitoring, white blood cell, oncology, medical device, chemotherapy, PointCheck, computer vision, at-home testing, febrile neutropenia, immunosuppression